Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes

Stephen J. Greene, Muthiah Vaduganathan, Muhammad Shahzeb Khan, George L. Bakris, Matthew R. Weir, Jonathan H. Seltzer, Naveed Sattar, Darren K McGuire, James L. Januzzi, Norman Stockbridge, Javed Butler

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Despite multiple examples of glucose-lowering therapies affecting heart failure (HF) risk, ascertainment of HF data in cardiovascular outcome trials of these medications has not been systematically characterized. In this review, large (n >1,000) published phase III and IV cardiovascular outcome trials evaluating glucose-lowering therapies through June 2017 were identified. Data were abstracted from publications, U.S. Food and Drug Administration advisory committee records, and U.S. Food and Drug Administration labeling documents. Overall, 21 trials including 152,737 patients were evaluated. Rates and definitions of baseline HF and incident HF were inconsistently provided. Baseline ejection fraction data were provided in 3 studies but not specific to patients with HF. No trial reported functional class, ejection fraction, or HF therapy at the time of incident HF diagnosis. HF hospitalization data were available in 15 trials, but only 2 included HF-related events within the primary composite endpoint. This systematic review highlights gaps in HF data capture within cardiovascular outcome trials of glucose-lowering therapies and outlines rationale and strategies for improving HF characterization.

Original languageEnglish (US)
Pages (from-to)1379-1390
Number of pages12
JournalJournal of the American College of Cardiology
Volume71
Issue number12
DOIs
StatePublished - Mar 27 2018

Fingerprint

Type 2 Diabetes Mellitus
Heart Failure
Glucose
Drug Labeling
Advisory Committees
United States Food and Drug Administration
Therapeutics
Publications
Hospitalization
Food

Keywords

  • clinical trial
  • diabetes mellitus
  • heart failure
  • medication
  • outcomes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Greene, S. J., Vaduganathan, M., Khan, M. S., Bakris, G. L., Weir, M. R., Seltzer, J. H., ... Butler, J. (2018). Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. Journal of the American College of Cardiology, 71(12), 1379-1390. https://doi.org/10.1016/j.jacc.2018.01.047

Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. / Greene, Stephen J.; Vaduganathan, Muthiah; Khan, Muhammad Shahzeb; Bakris, George L.; Weir, Matthew R.; Seltzer, Jonathan H.; Sattar, Naveed; McGuire, Darren K; Januzzi, James L.; Stockbridge, Norman; Butler, Javed.

In: Journal of the American College of Cardiology, Vol. 71, No. 12, 27.03.2018, p. 1379-1390.

Research output: Contribution to journalReview article

Greene, SJ, Vaduganathan, M, Khan, MS, Bakris, GL, Weir, MR, Seltzer, JH, Sattar, N, McGuire, DK, Januzzi, JL, Stockbridge, N & Butler, J 2018, 'Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes', Journal of the American College of Cardiology, vol. 71, no. 12, pp. 1379-1390. https://doi.org/10.1016/j.jacc.2018.01.047
Greene, Stephen J. ; Vaduganathan, Muthiah ; Khan, Muhammad Shahzeb ; Bakris, George L. ; Weir, Matthew R. ; Seltzer, Jonathan H. ; Sattar, Naveed ; McGuire, Darren K ; Januzzi, James L. ; Stockbridge, Norman ; Butler, Javed. / Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. In: Journal of the American College of Cardiology. 2018 ; Vol. 71, No. 12. pp. 1379-1390.
@article{919d1248836a4872ac11d4e7996cda00,
title = "Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes",
abstract = "Despite multiple examples of glucose-lowering therapies affecting heart failure (HF) risk, ascertainment of HF data in cardiovascular outcome trials of these medications has not been systematically characterized. In this review, large (n >1,000) published phase III and IV cardiovascular outcome trials evaluating glucose-lowering therapies through June 2017 were identified. Data were abstracted from publications, U.S. Food and Drug Administration advisory committee records, and U.S. Food and Drug Administration labeling documents. Overall, 21 trials including 152,737 patients were evaluated. Rates and definitions of baseline HF and incident HF were inconsistently provided. Baseline ejection fraction data were provided in 3 studies but not specific to patients with HF. No trial reported functional class, ejection fraction, or HF therapy at the time of incident HF diagnosis. HF hospitalization data were available in 15 trials, but only 2 included HF-related events within the primary composite endpoint. This systematic review highlights gaps in HF data capture within cardiovascular outcome trials of glucose-lowering therapies and outlines rationale and strategies for improving HF characterization.",
keywords = "clinical trial, diabetes mellitus, heart failure, medication, outcomes",
author = "Greene, {Stephen J.} and Muthiah Vaduganathan and Khan, {Muhammad Shahzeb} and Bakris, {George L.} and Weir, {Matthew R.} and Seltzer, {Jonathan H.} and Naveed Sattar and McGuire, {Darren K} and Januzzi, {James L.} and Norman Stockbridge and Javed Butler",
year = "2018",
month = "3",
day = "27",
doi = "10.1016/j.jacc.2018.01.047",
language = "English (US)",
volume = "71",
pages = "1379--1390",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "12",

}

TY - JOUR

T1 - Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes

AU - Greene, Stephen J.

AU - Vaduganathan, Muthiah

AU - Khan, Muhammad Shahzeb

AU - Bakris, George L.

AU - Weir, Matthew R.

AU - Seltzer, Jonathan H.

AU - Sattar, Naveed

AU - McGuire, Darren K

AU - Januzzi, James L.

AU - Stockbridge, Norman

AU - Butler, Javed

PY - 2018/3/27

Y1 - 2018/3/27

N2 - Despite multiple examples of glucose-lowering therapies affecting heart failure (HF) risk, ascertainment of HF data in cardiovascular outcome trials of these medications has not been systematically characterized. In this review, large (n >1,000) published phase III and IV cardiovascular outcome trials evaluating glucose-lowering therapies through June 2017 were identified. Data were abstracted from publications, U.S. Food and Drug Administration advisory committee records, and U.S. Food and Drug Administration labeling documents. Overall, 21 trials including 152,737 patients were evaluated. Rates and definitions of baseline HF and incident HF were inconsistently provided. Baseline ejection fraction data were provided in 3 studies but not specific to patients with HF. No trial reported functional class, ejection fraction, or HF therapy at the time of incident HF diagnosis. HF hospitalization data were available in 15 trials, but only 2 included HF-related events within the primary composite endpoint. This systematic review highlights gaps in HF data capture within cardiovascular outcome trials of glucose-lowering therapies and outlines rationale and strategies for improving HF characterization.

AB - Despite multiple examples of glucose-lowering therapies affecting heart failure (HF) risk, ascertainment of HF data in cardiovascular outcome trials of these medications has not been systematically characterized. In this review, large (n >1,000) published phase III and IV cardiovascular outcome trials evaluating glucose-lowering therapies through June 2017 were identified. Data were abstracted from publications, U.S. Food and Drug Administration advisory committee records, and U.S. Food and Drug Administration labeling documents. Overall, 21 trials including 152,737 patients were evaluated. Rates and definitions of baseline HF and incident HF were inconsistently provided. Baseline ejection fraction data were provided in 3 studies but not specific to patients with HF. No trial reported functional class, ejection fraction, or HF therapy at the time of incident HF diagnosis. HF hospitalization data were available in 15 trials, but only 2 included HF-related events within the primary composite endpoint. This systematic review highlights gaps in HF data capture within cardiovascular outcome trials of glucose-lowering therapies and outlines rationale and strategies for improving HF characterization.

KW - clinical trial

KW - diabetes mellitus

KW - heart failure

KW - medication

KW - outcomes

UR - http://www.scopus.com/inward/record.url?scp=85042620242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042620242&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2018.01.047

DO - 10.1016/j.jacc.2018.01.047

M3 - Review article

VL - 71

SP - 1379

EP - 1390

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 12

ER -